This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-106a-5p | AKT3 | -0.2 | 0.80221 | 0.46 | 0.53933 | miRNATAP | -0.55 | 0 | NA | |
2 | hsa-miR-106b-5p | AKT3 | -0.3 | 0.86929 | 0.46 | 0.53933 | miRNATAP | -0.91 | 0 | NA | |
3 | hsa-miR-107 | AKT3 | -0.04 | 0.98836 | 0.46 | 0.53933 | PITA; miRanda | -0.55 | 0.00017 | NA | |
4 | hsa-miR-1275 | AKT3 | -0.83 | 0.08038 | 0.46 | 0.53933 | PITA | -0.27 | 0 | NA | |
5 | hsa-miR-142-3p | AKT3 | -0.15 | 0.9461 | 0.46 | 0.53933 | miRanda | -0.2 | 0.00627 | NA | |
6 | hsa-miR-15a-5p | AKT3 | -0.07 | 0.96484 | 0.46 | 0.53933 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.72 | 0 | NA | |
7 | hsa-miR-15b-5p | AKT3 | -0.27 | 0.87097 | 0.46 | 0.53933 | miRNATAP | -0.67 | 0 | NA | |
8 | hsa-miR-16-5p | AKT3 | 0.01 | 0.99448 | 0.46 | 0.53933 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.75 | 0 | NA | |
9 | hsa-miR-17-3p | AKT3 | 0.1 | 0.96011 | 0.46 | 0.53933 | miRNATAP | -0.52 | 0 | NA | |
10 | hsa-miR-17-5p | AKT3 | -0.18 | 0.93454 | 0.46 | 0.53933 | TargetScan; miRNATAP | -0.63 | 0 | NA | |
11 | hsa-miR-181b-5p | AKT3 | 0.16 | 0.93018 | 0.46 | 0.53933 | miRNATAP | -0.27 | 0.00963 | NA | |
12 | hsa-miR-20a-5p | AKT3 | -0.18 | 0.92812 | 0.46 | 0.53933 | miRNATAP | -0.53 | 0 | NA | |
13 | hsa-miR-28-3p | AKT3 | -0.23 | 0.93535 | 0.46 | 0.53933 | miRNATAP | -0.52 | 0.00719 | NA | |
14 | hsa-miR-29a-3p | AKT3 | 0.01 | 0.99698 | 0.46 | 0.53933 | miRNATAP | -0.81 | 0 | NA | |
15 | hsa-miR-29b-3p | AKT3 | -0.1 | 0.95899 | 0.46 | 0.53933 | miRNATAP | -0.68 | 0 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
16 | hsa-miR-32-3p | AKT3 | -0.57 | 0.13133 | 0.46 | 0.53933 | mirMAP | -0.56 | 0 | NA | |
17 | hsa-miR-320a | AKT3 | -0.42 | 0.8402 | 0.46 | 0.53933 | PITA; miRanda; miRNATAP | -0.33 | 0.00138 | NA | |
18 | hsa-miR-320b | AKT3 | -0.24 | 0.85922 | 0.46 | 0.53933 | PITA; miRanda; miRNATAP | -0.25 | 0.00855 | NA | |
19 | hsa-miR-335-3p | AKT3 | -0.24 | 0.8845 | 0.46 | 0.53933 | mirMAP | -0.58 | 0 | NA | |
20 | hsa-miR-33a-3p | AKT3 | -0.79 | 0.01052 | 0.46 | 0.53933 | mirMAP | -0.49 | 0 | NA | |
21 | hsa-miR-340-5p | AKT3 | -0 | 0.99757 | 0.46 | 0.53933 | mirMAP | -0.28 | 0.006 | NA | |
22 | hsa-miR-362-3p | AKT3 | -0.72 | 0.03459 | 0.46 | 0.53933 | miRanda | -0.42 | 0 | NA | |
23 | hsa-miR-362-5p | AKT3 | -0.27 | 0.75202 | 0.46 | 0.53933 | PITA; TargetScan; miRNATAP | -0.52 | 0 | NA | |
24 | hsa-miR-369-3p | AKT3 | 0.12 | 0.8323 | 0.46 | 0.53933 | mirMAP | -0.23 | 0.00901 | NA | |
25 | hsa-miR-374a-5p | AKT3 | -0.34 | 0.76692 | 0.46 | 0.53933 | mirMAP | -0.58 | 0 | NA | |
26 | hsa-miR-374b-5p | AKT3 | -0.29 | 0.8357 | 0.46 | 0.53933 | mirMAP | -0.68 | 0 | NA | |
27 | hsa-miR-421 | AKT3 | -0.18 | 0.7347 | 0.46 | 0.53933 | miRanda; mirMAP | -0.46 | 0 | NA | |
28 | hsa-miR-424-5p | AKT3 | 0.25 | 0.87015 | 0.46 | 0.53933 | miRNATAP | -0.24 | 0.00104 | 26315541 | Silencing Akt3 and E2F3 by siRNA pheno-copied the effect of ectopic miR-424 on HCC growth; Whereas overexpression of Akt3 and E2F3 attenuated the effect of miR-424 on HCC growth |
29 | hsa-miR-501-3p | AKT3 | -0.75 | 0.55276 | 0.46 | 0.53933 | miRNATAP | -0.5 | 0 | NA | |
30 | hsa-miR-502-3p | AKT3 | -0.48 | 0.5143 | 0.46 | 0.53933 | miRNATAP | -0.64 | 0 | NA | |
31 | hsa-miR-502-5p | AKT3 | -0.71 | 0.02613 | 0.46 | 0.53933 | PITA; miRNATAP | -0.41 | 0 | NA | |
32 | hsa-miR-505-3p | AKT3 | -0.47 | 0.69038 | 0.46 | 0.53933 | mirMAP | -0.77 | 0 | 22051041 | We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR |
33 | hsa-miR-548o-3p | AKT3 | -0.19 | 0.51773 | 0.46 | 0.53933 | mirMAP | -0.31 | 8.0E-5 | NA | |
34 | hsa-miR-577 | AKT3 | -1.06 | 0.32606 | 0.46 | 0.53933 | mirMAP | -0.38 | 0 | NA | |
35 | hsa-miR-663b | AKT3 | 0.1 | 0.81499 | 0.46 | 0.53933 | PITA | -0.25 | 1.0E-5 | NA | |
36 | hsa-miR-769-5p | AKT3 | -0.31 | 0.7357 | 0.46 | 0.53933 | PITA; miRNATAP | -0.84 | 0 | NA | |
37 | hsa-miR-93-5p | AKT3 | -0.61 | 0.8253 | 0.46 | 0.53933 | miRNATAP | -0.76 | 0 | NA | |
38 | hsa-miR-708-3p | APAF1 | 0.14 | 0.89698 | -0.17 | 0.88665 | mirMAP | -0.11 | 0.0011 | NA | |
39 | hsa-miR-324-5p | ATM | -0.5 | 0.53742 | 0.19 | 0.86463 | miRanda | -0.12 | 0.00155 | NA | |
40 | hsa-miR-455-5p | ATM | -0.14 | 0.86574 | 0.19 | 0.86463 | miRanda | -0.12 | 0.00128 | NA | |
41 | hsa-miR-590-5p | ATM | -0.55 | 0.47274 | 0.19 | 0.86463 | mirMAP | -0.1 | 0.00142 | NA | |
42 | hsa-miR-17-5p | BCL2 | -0.18 | 0.93454 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.31 | 2.0E-5 | 25435430 | Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2 |
43 | hsa-miR-192-5p | BCL2 | -0.12 | 0.97293 | -0.87 | 0.24496 | miRNAWalker2 validate | -0.23 | 0.00056 | 26550150 | MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192 |
44 | hsa-miR-196b-5p | BCL2 | -0.08 | 0.97211 | -0.87 | 0.24496 | miRNAWalker2 validate | -0.13 | 0.00926 | NA | |
45 | hsa-miR-20a-3p | BCL2 | 0.46 | 0.57674 | -0.87 | 0.24496 | mirMAP | -0.19 | 0.00115 | NA | |
46 | hsa-miR-20a-5p | BCL2 | -0.18 | 0.92812 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.25 | 0.00046 | NA | |
47 | hsa-miR-224-3p | BCL2 | 0.11 | 0.74909 | -0.87 | 0.24496 | mirMAP | -0.18 | 0.00775 | 24796455 | In addition the expressions of Bcl2 mRNA and protein were 1.05 ± 0.04 and 0.21 ± 0.03 in the miR-224 ASO group significantly lower than that in the control group 4.87 ± 0.96 and 0.88 ± 0.09 P < 0.01 |
48 | hsa-miR-224-5p | BCL2 | -0.24 | 0.85735 | -0.87 | 0.24496 | mirMAP | -0.3 | 0 | 24796455 | In addition the expressions of Bcl2 mRNA and protein were 1.05 ± 0.04 and 0.21 ± 0.03 in the miR-224 ASO group significantly lower than that in the control group 4.87 ± 0.96 and 0.88 ± 0.09 P < 0.01 |
49 | hsa-miR-24-2-5p | BCL2 | -0.09 | 0.92016 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.41 | 0.00012 | NA | |
50 | hsa-miR-29a-3p | BCL2 | 0.01 | 0.99698 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.34 | 0.00194 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
51 | hsa-miR-29a-5p | BCL2 | -0.32 | 0.60044 | -0.87 | 0.24496 | mirMAP | -0.34 | 1.0E-5 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
52 | hsa-miR-29b-3p | BCL2 | -0.1 | 0.95899 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase | -0.27 | 0.00119 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
53 | hsa-miR-335-3p | BCL2 | -0.24 | 0.8845 | -0.87 | 0.24496 | mirMAP | -0.25 | 0.00118 | NA | |
54 | hsa-miR-33a-5p | BCL2 | -0.21 | 0.85331 | -0.87 | 0.24496 | mirMAP | -0.13 | 0.00456 | NA | |
55 | hsa-miR-450b-5p | BCL2 | -0.01 | 0.98315 | -0.87 | 0.24496 | mirMAP | -0.24 | 0.00586 | NA | |
56 | hsa-miR-452-5p | BCL2 | -0.05 | 0.97387 | -0.87 | 0.24496 | mirMAP | -0.28 | 0.00061 | NA | |
57 | hsa-miR-7-5p | BCL2 | 0.21 | 0.77371 | -0.87 | 0.24496 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.2 | 0.00018 | 26464649; 25862909; 21750649 | Western blotting was used to evaluate the effect of miR-7 on Bcl2 in A549 and H460 cells; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells;miR-7 overexpression correlated with diminished BCL2 expression but there was no relationship between miR-7 and EGFR expression neither in tumour samples nor in the cell lines; Of the two postulated miR-7 target genes we examined BCL2 but not EGFR seems to be a possible miR-7 target in OC;Bioinformatics predictions revealed a potential binding site of miR-7 on 3'UTR of BCL-2 and it was further confirmed by luciferase assay; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; These results suggest that miR-7 regulates the expression of BCL-2 through direct 3'UTR interactions |
58 | hsa-let-7a-5p | BCL2L1 | -0.06 | 0.98501 | 0.24 | 0.89096 | TargetScan; miRNATAP | -0.27 | 0.0015 | 26915294; 20347499 | As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA |
59 | hsa-miR-126-5p | BIRC2 | 0.08 | 0.95664 | -0.01 | 0.9934 | mirMAP | -0.12 | 0.00073 | NA | |
60 | hsa-miR-24-1-5p | BIRC3 | -0.19 | 0.79153 | -0.14 | 0.89724 | MirTarget | -0.31 | 0.00145 | NA | |
61 | hsa-miR-651-5p | BIRC3 | -0.57 | 0.17254 | -0.14 | 0.89724 | MirTarget | -0.16 | 0.00706 | NA | |
62 | hsa-miR-20a-3p | CAPN2 | 0.46 | 0.57674 | 0.04 | 0.98149 | MirTarget | -0.11 | 0.00146 | NA | |
63 | hsa-miR-421 | CAPN2 | -0.18 | 0.7347 | 0.04 | 0.98149 | miRanda | -0.25 | 0 | NA | |
64 | hsa-miR-7-5p | CAPN2 | 0.21 | 0.77371 | 0.04 | 0.98149 | miRNAWalker2 validate | -0.12 | 0.0001 | NA | |
65 | hsa-miR-181c-5p | CASP10 | 0.04 | 0.96916 | -0.29 | 0.80713 | mirMAP | -0.15 | 0.00318 | NA | |
66 | hsa-miR-30a-5p | CASP3 | 0.22 | 0.93395 | -0.16 | 0.90316 | miRNATAP | -0.2 | 6.0E-5 | NA | |
67 | hsa-miR-143-3p | CASP8 | 0.37 | 0.92734 | -0.27 | 0.82859 | MirTarget | -0.11 | 0.00055 | NA | |
68 | hsa-miR-130b-3p | CFLAR | -0.22 | 0.82466 | -0.06 | 0.9614 | mirMAP | -0.17 | 0 | NA | |
69 | hsa-miR-374b-5p | CFLAR | -0.29 | 0.8357 | -0.06 | 0.9614 | MirTarget | -0.16 | 0.00035 | NA | |
70 | hsa-miR-421 | CFLAR | -0.18 | 0.7347 | -0.06 | 0.9614 | miRanda | -0.11 | 0.00016 | NA | |
71 | hsa-miR-23b-3p | CHUK | -0.11 | 0.96135 | -0.1 | 0.93218 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.14 | 0.00997 | NA | |
72 | hsa-miR-15b-3p | CSF2RB | -0.56 | 0.60918 | -0.42 | 0.60801 | mirMAP | -0.56 | 0 | NA | |
73 | hsa-miR-186-5p | CSF2RB | -0.32 | 0.85413 | -0.42 | 0.60801 | mirMAP | -0.53 | 0.00037 | NA | |
74 | hsa-miR-19a-3p | CSF2RB | -0.21 | 0.84464 | -0.42 | 0.60801 | MirTarget | -0.51 | 0 | NA | |
75 | hsa-miR-19b-3p | CSF2RB | -0.03 | 0.98666 | -0.42 | 0.60801 | MirTarget | -0.67 | 0 | NA | |
76 | hsa-miR-30b-3p | CSF2RB | -0.51 | 0.16242 | -0.42 | 0.60801 | MirTarget | -0.43 | 2.0E-5 | NA | |
77 | hsa-miR-452-3p | CSF2RB | -0.17 | 0.79901 | -0.42 | 0.60801 | mirMAP | -0.43 | 0 | NA | |
78 | hsa-miR-532-5p | CSF2RB | -0.35 | 0.87895 | -0.42 | 0.60801 | MirTarget | -0.37 | 0.00041 | NA | |
79 | hsa-miR-576-5p | CSF2RB | -0.51 | 0.41719 | -0.42 | 0.60801 | miRNATAP | -0.36 | 0.0007 | NA | |
80 | hsa-miR-590-3p | CSF2RB | -0.28 | 0.59127 | -0.42 | 0.60801 | miRanda; mirMAP | -0.39 | 1.0E-5 | NA | |
81 | hsa-miR-625-5p | CSF2RB | -0.69 | 0.21031 | -0.42 | 0.60801 | MirTarget | -0.29 | 0.00017 | NA | |
82 | hsa-miR-139-5p | CYCS | -0.08 | 0.92869 | -0.08 | 0.96574 | miRanda | -0.18 | 7.0E-5 | NA | |
83 | hsa-miR-34c-3p | CYCS | -0.07 | 0.82545 | -0.08 | 0.96574 | mirMAP | -0.1 | 0.008 | NA | |
84 | hsa-miR-34c-5p | CYCS | -0.02 | 0.95279 | -0.08 | 0.96574 | miRanda | -0.16 | 0.00033 | NA | |
85 | hsa-miR-26a-5p | DFFA | 0.01 | 0.99772 | -0.29 | 0.79395 | mirMAP | -0.17 | 0.00684 | NA | |
86 | hsa-miR-30a-3p | DFFA | 0.25 | 0.91709 | -0.29 | 0.79395 | mirMAP | -0.15 | 0.00034 | NA | |
87 | hsa-miR-34c-5p | DFFA | -0.02 | 0.95279 | -0.29 | 0.79395 | miRanda | -0.11 | 0.00077 | NA | |
88 | hsa-miR-664a-3p | DFFA | -0 | 0.99612 | -0.29 | 0.79395 | mirMAP | -0.14 | 0.00043 | NA | |
89 | hsa-miR-19a-3p | ENDOD1 | -0.21 | 0.84464 | 0.04 | 0.97377 | mirMAP | -0.12 | 0.00066 | NA | |
90 | hsa-miR-19b-3p | ENDOD1 | -0.03 | 0.98666 | 0.04 | 0.97377 | mirMAP | -0.17 | 0.00013 | NA | |
91 | hsa-miR-20a-3p | ENDOD1 | 0.46 | 0.57674 | 0.04 | 0.97377 | MirTarget | -0.1 | 0.00063 | NA | |
92 | hsa-miR-335-3p | ENDOD1 | -0.24 | 0.8845 | 0.04 | 0.97377 | MirTarget | -0.11 | 0.00518 | NA | |
93 | hsa-miR-450b-5p | ENDOD1 | -0.01 | 0.98315 | 0.04 | 0.97377 | MirTarget; mirMAP | -0.12 | 0.00808 | NA | |
94 | hsa-miR-454-3p | ENDOD1 | -0.1 | 0.84355 | 0.04 | 0.97377 | MirTarget | -0.15 | 0.00321 | NA | |
95 | hsa-miR-106a-5p | FAS | -0.2 | 0.80221 | -0.35 | 0.70281 | miRNAWalker2 validate; miRTarBase | -0.31 | 0 | 22431000; 27142596 | miR 106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS; Bioinformatic analysis combining with validation experiments identified FAS as a direct target of miR-106a; Moreover a significant inverse correlation was found between miR-106a and FAS expression not only in gastric cancer cell lines but also in gastric cancer specimens; Taken together these findings suggest that ectopicly overexpressed miR-106a may play an oncogenic role in gastric carcinogenesis and impair extrinsic apoptotic pathway through targeting FAS;Functional experiment ascertained that miR-106a interacted with FAS and mediated caspase3 pathway |
96 | hsa-miR-361-5p | FAS | -0.14 | 0.9415 | -0.35 | 0.70281 | miRanda | -0.42 | 0.00016 | NA | |
97 | hsa-miR-590-5p | FAS | -0.55 | 0.47274 | -0.35 | 0.70281 | miRanda | -0.17 | 0.00403 | NA | |
98 | hsa-miR-98-5p | FAS | -0.17 | 0.8988 | -0.35 | 0.70281 | miRNAWalker2 validate | -0.38 | 2.0E-5 | NA | |
99 | hsa-miR-452-3p | FASLG | -0.17 | 0.79901 | -1.02 | 0.04975 | mirMAP | -0.3 | 0.00051 | NA | |
100 | hsa-miR-92a-3p | FASLG | 0.03 | 0.99325 | -1.02 | 0.04975 | miRNATAP | -0.38 | 0.00279 | NA | |
101 | hsa-miR-130b-5p | IL1R1 | -0.65 | 0.3791 | 0.1 | 0.93138 | mirMAP | -0.6 | 0 | NA | |
102 | hsa-miR-17-3p | IL1R1 | 0.1 | 0.96011 | 0.1 | 0.93138 | mirMAP | -0.55 | 0 | NA | |
103 | hsa-miR-186-5p | IL1R1 | -0.32 | 0.85413 | 0.1 | 0.93138 | mirMAP | -0.76 | 0 | NA | |
104 | hsa-miR-192-5p | IL1R1 | -0.12 | 0.97293 | 0.1 | 0.93138 | miRNAWalker2 validate | -0.52 | 0 | NA | |
105 | hsa-miR-197-3p | IL1R1 | -0.46 | 0.79492 | 0.1 | 0.93138 | miRNAWalker2 validate | -0.45 | 0 | NA | |
106 | hsa-miR-215-5p | IL1R1 | -0.14 | 0.94481 | 0.1 | 0.93138 | miRNAWalker2 validate | -0.13 | 0.00191 | NA | |
107 | hsa-miR-24-3p | IL1R1 | -0.05 | 0.98527 | 0.1 | 0.93138 | miRNATAP | -0.6 | 0.0002 | NA | |
108 | hsa-miR-26b-5p | IL1R1 | -0.02 | 0.99038 | 0.1 | 0.93138 | mirMAP | -0.73 | 0 | NA | |
109 | hsa-miR-30d-3p | IL1R1 | -0.12 | 0.81491 | 0.1 | 0.93138 | mirMAP | -0.63 | 0 | NA | |
110 | hsa-miR-335-3p | IL1R1 | -0.24 | 0.8845 | 0.1 | 0.93138 | mirMAP | -0.54 | 0 | NA | |
111 | hsa-miR-361-5p | IL1R1 | -0.14 | 0.9415 | 0.1 | 0.93138 | miRanda | -0.66 | 0 | NA | |
112 | hsa-miR-491-5p | IL1R1 | -0.59 | 0.04526 | 0.1 | 0.93138 | miRanda | -0.22 | 0.00269 | NA | |
113 | hsa-miR-548o-3p | IL1R1 | -0.19 | 0.51773 | 0.1 | 0.93138 | mirMAP | -0.32 | 2.0E-5 | NA | |
114 | hsa-miR-590-3p | IL1R1 | -0.28 | 0.59127 | 0.1 | 0.93138 | miRanda; miRNATAP | -0.49 | 0 | NA | |
115 | hsa-let-7f-2-3p | IL1RAP | -0.05 | 0.88212 | 0.16 | 0.83155 | MirTarget | -0.14 | 0.00022 | NA | |
116 | hsa-miR-106a-5p | IL1RAP | -0.2 | 0.80221 | 0.16 | 0.83155 | MirTarget | -0.19 | 2.0E-5 | NA | |
117 | hsa-miR-106b-5p | IL1RAP | -0.3 | 0.86929 | 0.16 | 0.83155 | MirTarget | -0.23 | 1.0E-5 | NA | |
118 | hsa-miR-130a-3p | IL1RAP | 0.09 | 0.9291 | 0.16 | 0.83155 | MirTarget | -0.18 | 0.0001 | NA | |
119 | hsa-miR-130b-3p | IL1RAP | -0.22 | 0.82466 | 0.16 | 0.83155 | MirTarget | -0.22 | 0 | NA | |
120 | hsa-miR-140-5p | IL1RAP | -0.23 | 0.84733 | 0.16 | 0.83155 | miRanda | -0.22 | 0.00096 | NA | |
121 | hsa-miR-17-5p | IL1RAP | -0.18 | 0.93454 | 0.16 | 0.83155 | MirTarget; TargetScan | -0.17 | 2.0E-5 | NA | |
122 | hsa-miR-186-5p | IL1RAP | -0.32 | 0.85413 | 0.16 | 0.83155 | mirMAP | -0.22 | 0.00072 | NA | |
123 | hsa-miR-192-5p | IL1RAP | -0.12 | 0.97293 | 0.16 | 0.83155 | miRNAWalker2 validate | -0.13 | 0.00026 | NA | |
124 | hsa-miR-19a-3p | IL1RAP | -0.21 | 0.84464 | 0.16 | 0.83155 | MirTarget | -0.17 | 1.0E-5 | NA | |
125 | hsa-miR-19b-3p | IL1RAP | -0.03 | 0.98666 | 0.16 | 0.83155 | MirTarget | -0.17 | 0.00017 | NA | |
126 | hsa-miR-20a-5p | IL1RAP | -0.18 | 0.92812 | 0.16 | 0.83155 | MirTarget | -0.14 | 0.00055 | NA | |
127 | hsa-miR-224-3p | IL1RAP | 0.11 | 0.74909 | 0.16 | 0.83155 | MirTarget | -0.11 | 0.00206 | NA | |
128 | hsa-miR-29a-3p | IL1RAP | 0.01 | 0.99698 | 0.16 | 0.83155 | MirTarget; miRNATAP | -0.19 | 0.00147 | NA | |
129 | hsa-miR-29b-3p | IL1RAP | -0.1 | 0.95899 | 0.16 | 0.83155 | MirTarget; miRNATAP | -0.21 | 0 | NA | |
130 | hsa-miR-301a-3p | IL1RAP | -0.11 | 0.83169 | 0.16 | 0.83155 | MirTarget | -0.11 | 0.00516 | NA | |
131 | hsa-miR-335-3p | IL1RAP | -0.24 | 0.8845 | 0.16 | 0.83155 | mirMAP | -0.13 | 0.00222 | NA | |
132 | hsa-miR-339-5p | IL1RAP | -0.3 | 0.71291 | 0.16 | 0.83155 | miRanda | -0.16 | 2.0E-5 | NA | |
133 | hsa-miR-362-3p | IL1RAP | -0.72 | 0.03459 | 0.16 | 0.83155 | miRanda | -0.12 | 0.00094 | NA | |
134 | hsa-miR-421 | IL1RAP | -0.18 | 0.7347 | 0.16 | 0.83155 | MirTarget; miRanda | -0.14 | 0.00093 | NA | |
135 | hsa-miR-454-3p | IL1RAP | -0.1 | 0.84355 | 0.16 | 0.83155 | MirTarget | -0.17 | 0.00132 | NA | |
136 | hsa-miR-576-5p | IL1RAP | -0.51 | 0.41719 | 0.16 | 0.83155 | mirMAP | -0.17 | 0.00017 | NA | |
137 | hsa-miR-590-3p | IL1RAP | -0.28 | 0.59127 | 0.16 | 0.83155 | MirTarget; miRanda; mirMAP | -0.14 | 0.00029 | NA | |
138 | hsa-miR-590-5p | IL1RAP | -0.55 | 0.47274 | 0.16 | 0.83155 | miRanda | -0.21 | 0 | NA | |
139 | hsa-miR-7-1-3p | IL1RAP | -0.46 | 0.6659 | 0.16 | 0.83155 | MirTarget | -0.12 | 0.00722 | NA | |
140 | hsa-miR-93-5p | IL1RAP | -0.61 | 0.8253 | 0.16 | 0.83155 | MirTarget | -0.15 | 0.00263 | NA | |
141 | hsa-miR-95-3p | IL1RAP | -0.08 | 0.92405 | 0.16 | 0.83155 | MirTarget | -0.11 | 0.00158 | NA | |
142 | hsa-miR-362-3p | IL3RA | -0.72 | 0.03459 | 0.16 | 0.80476 | miRanda | -0.17 | 0.0019 | NA | |
143 | hsa-miR-330-5p | IRAK1 | -0.28 | 0.81569 | 0.08 | 0.96334 | miRNAWalker2 validate | -0.2 | 0.00014 | NA | |
144 | hsa-miR-141-3p | IRAK3 | -0.32 | 0.87774 | 0.13 | 0.83349 | mirMAP | -0.47 | 0 | NA | |
145 | hsa-miR-148b-5p | IRAK3 | -0.24 | 0.43926 | 0.13 | 0.83349 | mirMAP | -0.26 | 0.00135 | NA | |
146 | hsa-miR-16-1-3p | IRAK3 | 0.15 | 0.73374 | 0.13 | 0.83349 | mirMAP | -0.26 | 0.00109 | NA | |
147 | hsa-miR-16-2-3p | IRAK3 | -0.37 | 0.54685 | 0.13 | 0.83349 | mirMAP | -0.37 | 1.0E-5 | NA | |
148 | hsa-miR-16-5p | IRAK3 | 0.01 | 0.99448 | 0.13 | 0.83349 | miRNAWalker2 validate | -0.4 | 9.0E-5 | NA | |
149 | hsa-miR-186-5p | IRAK3 | -0.32 | 0.85413 | 0.13 | 0.83349 | mirMAP | -0.41 | 0.0011 | NA | |
150 | hsa-miR-188-5p | IRAK3 | -0.57 | 0.32482 | 0.13 | 0.83349 | mirMAP | -0.35 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 32 | 1848 | 1.174e-22 | 5.464e-19 |
2 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 32 | 1929 | 4.393e-22 | 6.814e-19 |
3 | INTRACELLULAR SIGNAL TRANSDUCTION | 30 | 1572 | 4.13e-22 | 6.814e-19 |
4 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 28 | 1381 | 4.683e-21 | 5.448e-18 |
5 | RESPONSE TO NITROGEN COMPOUND | 22 | 859 | 3.466e-18 | 3.225e-15 |
6 | REGULATION OF CELL DEATH | 26 | 1472 | 7.754e-18 | 6.013e-15 |
7 | RESPONSE TO CYTOKINE | 20 | 714 | 3.437e-17 | 2.284e-14 |
8 | IMMUNE SYSTEM PROCESS | 28 | 1984 | 7.109e-17 | 3.675e-14 |
9 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 27 | 1791 | 6.996e-17 | 3.675e-14 |
10 | CELL DEATH | 22 | 1001 | 8.736e-17 | 3.695e-14 |
11 | APOPTOTIC SIGNALING PATHWAY | 15 | 289 | 8.63e-17 | 3.695e-14 |
12 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 9 | 39 | 1.948e-16 | 7.552e-14 |
13 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 11 | 99 | 3.709e-16 | 1.328e-13 |
14 | RESPONSE TO ENDOGENOUS STIMULUS | 24 | 1450 | 1.175e-15 | 3.904e-13 |
15 | NEGATIVE REGULATION OF CELL DEATH | 20 | 872 | 1.593e-15 | 4.942e-13 |
16 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 25 | 1656 | 1.858e-15 | 5.402e-13 |
17 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 24 | 1492 | 2.23e-15 | 6.104e-13 |
18 | POSITIVE REGULATION OF CELL COMMUNICATION | 24 | 1532 | 4.032e-15 | 1.042e-12 |
19 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 13 | 233 | 5.157e-15 | 1.263e-12 |
20 | REGULATION OF IMMUNE SYSTEM PROCESS | 23 | 1403 | 7.579e-15 | 1.679e-12 |
21 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 12 | 179 | 7.245e-15 | 1.679e-12 |
22 | REGULATION OF IMMUNE RESPONSE | 19 | 858 | 1.914e-14 | 4.049e-12 |
23 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 23 | 1518 | 4.083e-14 | 8.26e-12 |
24 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 12 | 213 | 5.874e-14 | 1.139e-11 |
25 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 18 | 799 | 8.548e-14 | 1.591e-11 |
26 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 18 | 876 | 4.081e-13 | 7.304e-11 |
27 | ACTIVATION OF IMMUNE RESPONSE | 14 | 427 | 5.952e-13 | 1.026e-10 |
28 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 9 | 95 | 9.81e-13 | 1.586e-10 |
29 | PHOSPHORYLATION | 20 | 1228 | 9.885e-13 | 1.586e-10 |
30 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 24 | 1977 | 1.119e-12 | 1.736e-10 |
31 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 9 | 98 | 1.307e-12 | 1.962e-10 |
32 | POSITIVE REGULATION OF IMMUNE RESPONSE | 15 | 563 | 1.504e-12 | 2.186e-10 |
33 | POSITIVE REGULATION OF CELL DEATH | 15 | 605 | 4.203e-12 | 5.888e-10 |
34 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 15 | 606 | 4.303e-12 | 5.888e-10 |
35 | ZYMOGEN ACTIVATION | 9 | 112 | 4.455e-12 | 5.923e-10 |
36 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 14 | 505 | 5.703e-12 | 7.372e-10 |
37 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 10 | 171 | 6.314e-12 | 7.94e-10 |
38 | REGULATION OF KINASE ACTIVITY | 16 | 776 | 1.105e-11 | 1.353e-09 |
39 | PROTEIN PHOSPHORYLATION | 17 | 944 | 1.787e-11 | 2.132e-09 |
40 | REGULATION OF TRANSFERASE ACTIVITY | 17 | 946 | 1.848e-11 | 2.149e-09 |
41 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 7 | 49 | 1.978e-11 | 2.245e-09 |
42 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 8 | 85 | 2.088e-11 | 2.313e-09 |
43 | CYTOKINE MEDIATED SIGNALING PATHWAY | 13 | 452 | 2.364e-11 | 2.559e-09 |
44 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 12 | 363 | 3.148e-11 | 3.329e-09 |
45 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 13 | 7.304e-11 | 7.552e-09 |
46 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 9 | 153 | 7.528e-11 | 7.578e-09 |
47 | REGULATION OF PEPTIDASE ACTIVITY | 12 | 392 | 7.655e-11 | 7.578e-09 |
48 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 9 | 154 | 7.982e-11 | 7.737e-09 |
49 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 8 | 109 | 1.581e-10 | 1.458e-08 |
50 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 6 | 34 | 1.548e-10 | 1.458e-08 |
51 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 11 | 321 | 1.598e-10 | 1.458e-08 |
52 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 11 | 323 | 1.707e-10 | 1.527e-08 |
53 | NEURON APOPTOTIC PROCESS | 6 | 35 | 1.865e-10 | 1.637e-08 |
54 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 17 | 1135 | 3.163e-10 | 2.726e-08 |
55 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 8 | 120 | 3.43e-10 | 2.847e-08 |
56 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 17 | 3.487e-10 | 2.847e-08 |
57 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 5 | 17 | 3.487e-10 | 2.847e-08 |
58 | HOMEOSTATIC PROCESS | 18 | 1337 | 4.503e-10 | 3.612e-08 |
59 | PROTEIN MATURATION | 10 | 265 | 4.736e-10 | 3.735e-08 |
60 | REGULATION OF PROTEOLYSIS | 14 | 711 | 5.223e-10 | 4.051e-08 |
61 | POSITIVE REGULATION OF DEFENSE RESPONSE | 11 | 364 | 6.051e-10 | 4.616e-08 |
62 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 15 | 867 | 6.524e-10 | 4.896e-08 |
63 | CHEMICAL HOMEOSTASIS | 15 | 874 | 7.287e-10 | 5.382e-08 |
64 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 9 | 200 | 8.193e-10 | 5.957e-08 |
65 | ACTIVATION OF INNATE IMMUNE RESPONSE | 9 | 204 | 9.76e-10 | 6.987e-08 |
66 | NEURON DEATH | 6 | 47 | 1.208e-09 | 8.514e-08 |
67 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 19 | 1618 | 1.239e-09 | 8.601e-08 |
68 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 8 | 142 | 1.318e-09 | 9.018e-08 |
69 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 22 | 1.471e-09 | 9.92e-08 |
70 | RESPONSE TO PEPTIDE | 11 | 404 | 1.809e-09 | 1.203e-07 |
71 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 51 | 2.011e-09 | 1.306e-07 |
72 | REGULATION OF RESPONSE TO STRESS | 18 | 1468 | 2.02e-09 | 1.306e-07 |
73 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 8 | 152 | 2.263e-09 | 1.442e-07 |
74 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 7 | 95 | 2.348e-09 | 1.476e-07 |
75 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 2.952e-09 | 1.832e-07 |
76 | REGULATION OF PROTEIN MODIFICATION PROCESS | 19 | 1710 | 3.122e-09 | 1.898e-07 |
77 | RESPONSE TO TUMOR NECROSIS FACTOR | 9 | 233 | 3.141e-09 | 1.898e-07 |
78 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 6 | 55 | 3.215e-09 | 1.918e-07 |
79 | RENAL SYSTEM PROCESS | 7 | 102 | 3.875e-09 | 2.283e-07 |
80 | RESPONSE TO WOUNDING | 12 | 563 | 4.688e-09 | 2.727e-07 |
81 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 9 | 246 | 5.049e-09 | 2.897e-07 |
82 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 15 | 1008 | 5.105e-09 | 2.897e-07 |
83 | RESPONSE TO ABIOTIC STIMULUS | 15 | 1024 | 6.316e-09 | 3.54e-07 |
84 | REGULATION OF INNATE IMMUNE RESPONSE | 10 | 357 | 8.339e-09 | 4.619e-07 |
85 | WOUND HEALING | 11 | 470 | 8.725e-09 | 4.667e-07 |
86 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 470 | 8.725e-09 | 4.667e-07 |
87 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 11 | 8.726e-09 | 4.667e-07 |
88 | RESPONSE TO BIOTIC STIMULUS | 14 | 886 | 8.831e-09 | 4.67e-07 |
89 | RESPONSE TO HORMONE | 14 | 893 | 9.758e-09 | 5.102e-07 |
90 | POSITIVE REGULATION OF KINASE ACTIVITY | 11 | 482 | 1.132e-08 | 5.851e-07 |
91 | CELLULAR RESPONSE TO PEPTIDE | 9 | 274 | 1.289e-08 | 6.59e-07 |
92 | REGULATION OF DEFENSE RESPONSE | 13 | 759 | 1.304e-08 | 6.594e-07 |
93 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 8 | 193 | 1.482e-08 | 7.414e-07 |
94 | RENAL WATER HOMEOSTASIS | 5 | 34 | 1.522e-08 | 7.455e-07 |
95 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 9 | 279 | 1.507e-08 | 7.455e-07 |
96 | CELLULAR GLUCOSE HOMEOSTASIS | 6 | 75 | 2.156e-08 | 1.045e-06 |
97 | LEUKOCYTE DIFFERENTIATION | 9 | 292 | 2.234e-08 | 1.071e-06 |
98 | FC RECEPTOR SIGNALING PATHWAY | 8 | 206 | 2.463e-08 | 1.17e-06 |
99 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 4 | 14 | 2.633e-08 | 1.238e-06 |
100 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 5 | 38 | 2.726e-08 | 1.269e-06 |
101 | RESPONSE TO BACTERIUM | 11 | 528 | 2.884e-08 | 1.329e-06 |
102 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 8 | 211 | 2.968e-08 | 1.354e-06 |
103 | HEMOSTASIS | 9 | 311 | 3.841e-08 | 1.735e-06 |
104 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 7 | 144 | 4.283e-08 | 1.916e-06 |
105 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 11 | 552 | 4.537e-08 | 2.011e-06 |
106 | CELL ACTIVATION | 11 | 568 | 6.065e-08 | 2.662e-06 |
107 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 17 | 6.229e-08 | 2.688e-06 |
108 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 14 | 1036 | 6.298e-08 | 2.688e-06 |
109 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 14 | 1036 | 6.298e-08 | 2.688e-06 |
110 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 8 | 235 | 6.833e-08 | 2.89e-06 |
111 | LYMPHOCYTE ACTIVATION | 9 | 342 | 8.655e-08 | 3.628e-06 |
112 | RESPONSE TO GLUCAGON | 5 | 48 | 9.14e-08 | 3.797e-06 |
113 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 14 | 1079 | 1.042e-07 | 4.291e-06 |
114 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 5 | 50 | 1.127e-07 | 4.6e-06 |
115 | LIPID PHOSPHORYLATION | 6 | 99 | 1.15e-07 | 4.653e-06 |
116 | LEUKOCYTE CELL CELL ADHESION | 8 | 255 | 1.281e-07 | 5.137e-06 |
117 | IMMUNE RESPONSE | 14 | 1100 | 1.322e-07 | 5.257e-06 |
118 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 9 | 360 | 1.338e-07 | 5.277e-06 |
119 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 11 | 616 | 1.376e-07 | 5.38e-06 |
120 | POSITIVE REGULATION OF PROTEOLYSIS | 9 | 363 | 1.436e-07 | 5.532e-06 |
121 | REGULATION OF CELL PROLIFERATION | 16 | 1496 | 1.438e-07 | 5.532e-06 |
122 | NECROPTOTIC PROCESS | 4 | 21 | 1.556e-07 | 5.885e-06 |
123 | POSITIVE REGULATION OF PROTEIN IMPORT | 6 | 104 | 1.544e-07 | 5.885e-06 |
124 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 9 | 370 | 1.688e-07 | 6.334e-06 |
125 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 9 | 372 | 1.767e-07 | 6.576e-06 |
126 | EXECUTION PHASE OF APOPTOSIS | 5 | 55 | 1.834e-07 | 6.773e-06 |
127 | REGULATION OF HYDROLASE ACTIVITY | 15 | 1327 | 1.958e-07 | 7.174e-06 |
128 | REGULATION OF PROTEIN IMPORT | 7 | 183 | 2.21e-07 | 8.035e-06 |
129 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 5 | 58 | 2.403e-07 | 8.602e-06 |
130 | RESPONSE TO AMINO ACID | 6 | 112 | 2.4e-07 | 8.602e-06 |
131 | CELLULAR RESPONSE TO STRESS | 16 | 1565 | 2.667e-07 | 9.474e-06 |
132 | REGULATION OF ORGANELLE ORGANIZATION | 14 | 1178 | 3.058e-07 | 1.078e-05 |
133 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 6 | 118 | 3.271e-07 | 1.144e-05 |
134 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 7 | 195 | 3.4e-07 | 1.181e-05 |
135 | NEGATIVE REGULATION OF CELL COMMUNICATION | 14 | 1192 | 3.531e-07 | 1.217e-05 |
136 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 121 | 3.795e-07 | 1.298e-05 |
137 | REGULATION OF NECROTIC CELL DEATH | 4 | 26 | 3.852e-07 | 1.308e-05 |
138 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 11 | 684 | 3.916e-07 | 1.32e-05 |
139 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 8 | 297 | 4.094e-07 | 1.37e-05 |
140 | LEUKOCYTE ACTIVATION | 9 | 414 | 4.345e-07 | 1.444e-05 |
141 | INOSITOL LIPID MEDIATED SIGNALING | 6 | 124 | 4.386e-07 | 1.447e-05 |
142 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 7 | 203 | 4.462e-07 | 1.462e-05 |
143 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 126 | 4.82e-07 | 1.568e-05 |
144 | CELLULAR RESPONSE TO HORMONE STIMULUS | 10 | 552 | 4.885e-07 | 1.578e-05 |
145 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 4 | 28 | 5.258e-07 | 1.676e-05 |
146 | NECROTIC CELL DEATH | 4 | 28 | 5.258e-07 | 1.676e-05 |
147 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 129 | 5.538e-07 | 1.753e-05 |
148 | RESPONSE TO OXYGEN LEVELS | 8 | 311 | 5.8e-07 | 1.824e-05 |
149 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 29 | 6.089e-07 | 1.889e-05 |
150 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 29 | 6.089e-07 | 1.889e-05 |
151 | WATER HOMEOSTASIS | 5 | 70 | 6.216e-07 | 1.903e-05 |
152 | REGULATION OF MEMBRANE PERMEABILITY | 5 | 70 | 6.216e-07 | 1.903e-05 |
153 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 6 | 132 | 6.341e-07 | 1.928e-05 |
154 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 5 | 71 | 6.675e-07 | 2.017e-05 |
155 | RESPONSE TO LIPID | 12 | 888 | 6.767e-07 | 2.031e-05 |
156 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 4 | 30 | 7.013e-07 | 2.092e-05 |
157 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 218 | 7.21e-07 | 2.137e-05 |
158 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 7 | 220 | 7.666e-07 | 2.258e-05 |
159 | IMMUNE SYSTEM DEVELOPMENT | 10 | 582 | 7.911e-07 | 2.315e-05 |
160 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 12 | 905 | 8.27e-07 | 2.405e-05 |
161 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 12 | 917 | 9.503e-07 | 2.746e-05 |
162 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 7 | 228 | 9.739e-07 | 2.797e-05 |
163 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 4 | 33 | 1.042e-06 | 2.938e-05 |
164 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 4 | 33 | 1.042e-06 | 2.938e-05 |
165 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 4 | 33 | 1.042e-06 | 2.938e-05 |
166 | T CELL RECEPTOR SIGNALING PATHWAY | 6 | 146 | 1.145e-06 | 3.211e-05 |
167 | T CELL HOMEOSTASIS | 4 | 34 | 1.179e-06 | 3.284e-05 |
168 | REGULATION OF INTRACELLULAR TRANSPORT | 10 | 621 | 1.422e-06 | 3.939e-05 |
169 | NIK NF KAPPAB SIGNALING | 5 | 83 | 1.458e-06 | 4.013e-05 |
170 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 36 | 1.492e-06 | 4.084e-05 |
171 | GLYCEROLIPID METABOLIC PROCESS | 8 | 356 | 1.599e-06 | 4.351e-05 |
172 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 14 | 1360 | 1.719e-06 | 4.651e-05 |
173 | PHOSPHOLIPID METABOLIC PROCESS | 8 | 364 | 1.887e-06 | 5.075e-05 |
174 | REGULATION OF NECROPTOTIC PROCESS | 3 | 11 | 1.981e-06 | 5.296e-05 |
175 | RESPONSE TO EXTERNAL STIMULUS | 16 | 1821 | 2.038e-06 | 5.417e-05 |
176 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 4 | 40 | 2.299e-06 | 6.009e-05 |
177 | REGULATION OF BODY FLUID LEVELS | 9 | 506 | 2.291e-06 | 6.009e-05 |
178 | LEUKOCYTE MIGRATION | 7 | 259 | 2.277e-06 | 6.009e-05 |
179 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 5 | 92 | 2.43e-06 | 6.317e-05 |
180 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 11 | 829 | 2.575e-06 | 6.657e-05 |
181 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 9 | 514 | 2.605e-06 | 6.698e-05 |
182 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 12 | 2.636e-06 | 6.74e-05 |
183 | PROTEOLYSIS | 13 | 1208 | 2.728e-06 | 6.936e-05 |
184 | GLUCOSE HOMEOSTASIS | 6 | 170 | 2.777e-06 | 6.986e-05 |
185 | CARBOHYDRATE HOMEOSTASIS | 6 | 170 | 2.777e-06 | 6.986e-05 |
186 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 43 | 3.088e-06 | 7.685e-05 |
187 | CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 4 | 43 | 3.088e-06 | 7.685e-05 |
188 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 7 | 272 | 3.147e-06 | 7.79e-05 |
189 | HEPATOCYTE APOPTOTIC PROCESS | 3 | 13 | 3.422e-06 | 8.336e-05 |
190 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 3 | 13 | 3.422e-06 | 8.336e-05 |
191 | RESPONSE TO COBALT ION | 3 | 13 | 3.422e-06 | 8.336e-05 |
192 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 4 | 46 | 4.063e-06 | 9.846e-05 |
193 | REGULATION OF LIPID KINASE ACTIVITY | 4 | 48 | 4.828e-06 | 0.0001164 |
194 | PROTEIN DEPHOSPHORYLATION | 6 | 190 | 5.276e-06 | 0.0001265 |
195 | T CELL APOPTOTIC PROCESS | 3 | 15 | 5.426e-06 | 0.0001295 |
196 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 12 | 1087 | 5.564e-06 | 0.0001321 |
197 | REGULATION OF NEURON APOPTOTIC PROCESS | 6 | 192 | 5.603e-06 | 0.0001323 |
198 | LYMPHOCYTE HOMEOSTASIS | 4 | 50 | 5.694e-06 | 0.0001338 |
199 | CELLULAR CHEMICAL HOMEOSTASIS | 9 | 570 | 6.037e-06 | 0.0001412 |
200 | REGULATION OF CATABOLIC PROCESS | 10 | 731 | 6.081e-06 | 0.0001415 |
201 | REGULATION OF PROTEIN TARGETING | 7 | 307 | 6.967e-06 | 0.0001613 |
202 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 4 | 53 | 7.203e-06 | 0.0001659 |
203 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 17 | 8.082e-06 | 0.0001843 |
204 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 8.082e-06 | 0.0001843 |
205 | POSITIVE REGULATION OF TRANSPORT | 11 | 936 | 8.223e-06 | 0.0001866 |
206 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 450 | 8.988e-06 | 0.000203 |
207 | LYMPHOCYTE DIFFERENTIATION | 6 | 209 | 9.105e-06 | 0.0002047 |
208 | LIPID MODIFICATION | 6 | 210 | 9.357e-06 | 0.0002093 |
209 | REGULATION OF PROTEIN LOCALIZATION | 11 | 950 | 9.462e-06 | 0.0002107 |
210 | INFLAMMATORY RESPONSE | 8 | 454 | 9.586e-06 | 0.0002124 |
211 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 3 | 18 | 9.682e-06 | 0.0002125 |
212 | LYMPHOCYTE APOPTOTIC PROCESS | 3 | 18 | 9.682e-06 | 0.0002125 |
213 | SINGLE ORGANISM CELL ADHESION | 8 | 459 | 1.038e-05 | 0.0002267 |
214 | REGULATION OF MITOCHONDRION ORGANIZATION | 6 | 218 | 1.158e-05 | 0.0002517 |
215 | REGULATION OF GLUCOSE IMPORT | 4 | 60 | 1.185e-05 | 0.0002553 |
216 | LEUKOCYTE HOMEOSTASIS | 4 | 60 | 1.185e-05 | 0.0002553 |
217 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 4 | 61 | 1.266e-05 | 0.0002715 |
218 | B CELL ACTIVATION | 5 | 132 | 1.425e-05 | 0.0003042 |
219 | REGULATION OF CYTOPLASMIC TRANSPORT | 8 | 481 | 1.456e-05 | 0.0003095 |
220 | IMMUNE EFFECTOR PROCESS | 8 | 486 | 1.569e-05 | 0.0003319 |
221 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 3 | 23 | 2.084e-05 | 0.0004368 |
222 | LEUKOCYTE APOPTOTIC PROCESS | 3 | 23 | 2.084e-05 | 0.0004368 |
223 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 7 | 365 | 2.136e-05 | 0.0004457 |
224 | I KAPPAB KINASE NF KAPPAB SIGNALING | 4 | 70 | 2.191e-05 | 0.000455 |
225 | CELLULAR HOMEOSTASIS | 9 | 676 | 2.354e-05 | 0.0004867 |
226 | REGULATION OF ANOIKIS | 3 | 24 | 2.378e-05 | 0.0004874 |
227 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 3 | 24 | 2.378e-05 | 0.0004874 |
228 | NEGATIVE REGULATION OF KINASE ACTIVITY | 6 | 250 | 2.511e-05 | 0.0005125 |
229 | REGULATION OF NEURON DEATH | 6 | 252 | 2.626e-05 | 0.0005336 |
230 | CELLULAR EXTRAVASATION | 3 | 25 | 2.698e-05 | 0.0005434 |
231 | EPITHELIAL CELL APOPTOTIC PROCESS | 3 | 25 | 2.698e-05 | 0.0005434 |
232 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 4 | 74 | 2.73e-05 | 0.0005475 |
233 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 7 | 381 | 2.811e-05 | 0.0005613 |
234 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 6 | 258 | 2.997e-05 | 0.0005959 |
235 | NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 5 | 156 | 3.188e-05 | 0.0006313 |
236 | LIPID BIOSYNTHETIC PROCESS | 8 | 539 | 3.292e-05 | 0.000649 |
237 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 6 | 263 | 3.337e-05 | 0.0006551 |
238 | INSULIN RECEPTOR SIGNALING PATHWAY | 4 | 80 | 3.714e-05 | 0.0007261 |
239 | REGULATION OF PROTEIN MATURATION | 4 | 82 | 4.093e-05 | 0.0007969 |
240 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 3 | 29 | 4.258e-05 | 0.0008255 |
241 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 5 | 167 | 4.416e-05 | 0.0008526 |
242 | RESPONSE TO CARBOHYDRATE | 5 | 168 | 4.544e-05 | 0.0008736 |
243 | NEGATIVE REGULATION OF B CELL ACTIVATION | 3 | 30 | 4.723e-05 | 0.0009044 |
244 | NEGATIVE REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 170 | 4.807e-05 | 0.0009167 |
245 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 6 | 282 | 4.923e-05 | 0.0009312 |
246 | REGULATION OF LIPID METABOLIC PROCESS | 6 | 282 | 4.923e-05 | 0.0009312 |
247 | STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 173 | 5.225e-05 | 0.0009802 |
248 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 3 | 31 | 5.22e-05 | 0.0009802 |
249 | DEPHOSPHORYLATION | 6 | 286 | 5.324e-05 | 0.0009949 |
250 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 4 | 88 | 5.401e-05 | 0.001001 |
251 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 4 | 88 | 5.401e-05 | 0.001001 |
252 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 32 | 5.751e-05 | 0.001049 |
253 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 3 | 32 | 5.751e-05 | 0.001049 |
254 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 3 | 32 | 5.751e-05 | 0.001049 |
255 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 3 | 32 | 5.751e-05 | 0.001049 |
256 | MITOCHONDRIAL TRANSPORT | 5 | 177 | 5.824e-05 | 0.001059 |
257 | RESPONSE TO DRUG | 7 | 431 | 6.141e-05 | 0.001112 |
258 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 10 | 957 | 6.177e-05 | 0.001114 |
259 | REGULATION OF INFLAMMATORY RESPONSE | 6 | 294 | 6.203e-05 | 0.001114 |
260 | MITOCHONDRION ORGANIZATION | 8 | 594 | 6.534e-05 | 0.001169 |
261 | REGULATION OF MYELOID CELL DIFFERENTIATION | 5 | 183 | 6.821e-05 | 0.001216 |
262 | NEGATIVE REGULATION OF PROTEIN PROCESSING | 3 | 35 | 7.551e-05 | 0.001336 |
263 | NEGATIVE REGULATION OF PROTEIN MATURATION | 3 | 35 | 7.551e-05 | 0.001336 |
264 | MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 96 | 7.59e-05 | 0.001338 |
265 | CELL CELL ADHESION | 8 | 608 | 7.689e-05 | 0.00135 |
266 | MYELOID CELL DIFFERENTIATION | 5 | 189 | 7.946e-05 | 0.00139 |
267 | RESPONSE TO REACTIVE OXYGEN SPECIES | 5 | 191 | 8.351e-05 | 0.001455 |
268 | REGULATION OF GLUCOSE TRANSPORT | 4 | 100 | 8.898e-05 | 0.001545 |
269 | RESPONSE TO ACID CHEMICAL | 6 | 319 | 9.726e-05 | 0.001682 |
270 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 103 | 9.981e-05 | 0.00172 |
271 | DEFENSE RESPONSE | 11 | 1231 | 0.0001025 | 0.00176 |
272 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 3 | 39 | 0.0001047 | 0.001792 |
273 | MITOTIC SPINDLE ASSEMBLY | 3 | 41 | 0.0001218 | 0.002068 |
274 | MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS | 3 | 41 | 0.0001218 | 0.002068 |
275 | REGULATION OF CELL ACTIVATION | 7 | 484 | 0.0001266 | 0.002143 |
276 | REGULATION OF NIK NF KAPPAB SIGNALING | 3 | 42 | 0.0001309 | 0.002199 |
277 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 3 | 42 | 0.0001309 | 0.002199 |
278 | MYELOID LEUKOCYTE MEDIATED IMMUNITY | 3 | 43 | 0.0001405 | 0.002352 |
279 | REGULATION OF CELLULAR LOCALIZATION | 11 | 1277 | 0.000142 | 0.002368 |
280 | REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 5 | 217 | 0.000152 | 0.002526 |
281 | RESPONSE TO INTERLEUKIN 1 | 4 | 115 | 0.0001529 | 0.002532 |
282 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 6 | 351 | 0.0001638 | 0.002703 |
283 | RESPONSE TO OXIDATIVE STRESS | 6 | 352 | 0.0001664 | 0.002736 |
284 | SYSTEM PROCESS | 13 | 1785 | 0.00017 | 0.002786 |
285 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 3 | 47 | 0.0001834 | 0.002995 |
286 | REGULATION OF B CELL ACTIVATION | 4 | 121 | 0.0001859 | 0.003025 |
287 | ORGANOPHOSPHATE METABOLIC PROCESS | 9 | 885 | 0.0001869 | 0.003031 |
288 | T CELL DIFFERENTIATION | 4 | 123 | 0.000198 | 0.003199 |
289 | EMBRYO DEVELOPMENT | 9 | 894 | 0.0002016 | 0.003246 |
290 | REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 49 | 0.0002077 | 0.003333 |
291 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 5 | 233 | 0.0002116 | 0.003384 |
292 | RESPONSE TO GAMMA RADIATION | 3 | 50 | 0.0002206 | 0.003516 |
293 | MUSCLE CELL DIFFERENTIATION | 5 | 237 | 0.000229 | 0.003637 |
294 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 4 | 128 | 0.0002307 | 0.003651 |
295 | RESPONSE TO NICOTINE | 3 | 51 | 0.000234 | 0.003691 |
296 | CELLULAR LIPID METABOLIC PROCESS | 9 | 913 | 0.0002359 | 0.003708 |
297 | NUCLEAR IMPORT | 4 | 129 | 0.0002377 | 0.003724 |
298 | RESPONSE TO TOXIC SUBSTANCE | 5 | 241 | 0.0002474 | 0.003863 |
299 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 7 | 541 | 0.0002508 | 0.00389 |
300 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 7 | 541 | 0.0002508 | 0.00389 |
301 | NEGATIVE REGULATION OF ORGANELLE ORGANIZATION | 6 | 387 | 0.0002774 | 0.004273 |
302 | RESPONSE TO VIRUS | 5 | 247 | 0.0002772 | 0.004273 |
303 | REGULATION OF AUTOPHAGY | 5 | 249 | 0.0002877 | 0.004417 |
304 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 7 | 554 | 0.0002897 | 0.004435 |
305 | REGULATION OF B CELL PROLIFERATION | 3 | 55 | 0.0002929 | 0.00446 |
306 | NEGATIVE REGULATION OF NECROTIC CELL DEATH | 2 | 11 | 0.0002933 | 0.00446 |
307 | RESPONSE TO ALKALOID | 4 | 137 | 0.0002991 | 0.004533 |
308 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 4 | 138 | 0.0003075 | 0.004645 |
309 | PLATELET ACTIVATION | 4 | 142 | 0.0003428 | 0.005162 |
310 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 6 | 404 | 0.000349 | 0.005238 |
311 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 7 | 573 | 0.0003552 | 0.005315 |
312 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 3 | 59 | 0.0003605 | 0.005377 |
313 | RESPONSE TO IONIZING RADIATION | 4 | 145 | 0.0003711 | 0.005516 |
314 | AGING | 5 | 264 | 0.0003763 | 0.005576 |
315 | ESTABLISHMENT OF LOCALIZATION IN CELL | 12 | 1676 | 0.0003775 | 0.005576 |
316 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 3 | 60 | 0.0003789 | 0.005579 |
317 | CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 146 | 0.0003809 | 0.005591 |
318 | REGULATION OF RESPONSE TO WOUNDING | 6 | 413 | 0.0003923 | 0.005723 |
319 | RESPONSE TO RADIATION | 6 | 413 | 0.0003923 | 0.005723 |
320 | RESPONSE TO TEMPERATURE STIMULUS | 4 | 148 | 0.000401 | 0.005831 |
321 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 9 | 983 | 0.0004068 | 0.005896 |
322 | REGULATION OF PROTEIN POLYUBIQUITINATION | 2 | 13 | 0.0004147 | 0.005993 |
323 | NEGATIVE REGULATION OF PHOSPHORYLATION | 6 | 422 | 0.0004398 | 0.006336 |
324 | PROTEIN IMPORT | 4 | 155 | 0.0004776 | 0.006859 |
325 | TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 2 | 14 | 0.0004831 | 0.006874 |
326 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.0004831 | 0.006874 |
327 | T CELL MIGRATION | 2 | 14 | 0.0004831 | 0.006874 |
328 | PROTEIN LOCALIZATION TO NUCLEUS | 4 | 156 | 0.0004893 | 0.006942 |
329 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 8 | 801 | 0.0005024 | 0.007105 |
330 | NEGATIVE REGULATION OF CELL CYCLE | 6 | 433 | 0.0005039 | 0.007105 |
331 | PROTEIN OLIGOMERIZATION | 6 | 434 | 0.00051 | 0.00717 |
332 | POSITIVE REGULATION OF GENE EXPRESSION | 12 | 1733 | 0.000512 | 0.007174 |
333 | NEGATIVE REGULATION OF CELL ACTIVATION | 4 | 158 | 0.0005134 | 0.007174 |
334 | POSITIVE REGULATION OF NEURON DEATH | 3 | 67 | 0.0005244 | 0.007305 |
335 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 6 | 437 | 0.0005289 | 0.007346 |
336 | NEGATIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 3 | 68 | 0.0005476 | 0.007564 |
337 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 7 | 616 | 0.0005478 | 0.007564 |
338 | RESPIRATORY BURST | 2 | 15 | 0.0005566 | 0.007595 |
339 | NEGATIVE REGULATION OF B CELL PROLIFERATION | 2 | 15 | 0.0005566 | 0.007595 |
340 | APOPTOTIC DNA FRAGMENTATION | 2 | 15 | 0.0005566 | 0.007595 |
341 | REGULATION OF VIRAL INDUCED CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 2 | 15 | 0.0005566 | 0.007595 |
342 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 5 | 289 | 0.0005682 | 0.00773 |
343 | NEGATIVE REGULATION OF LEUKOCYTE PROLIFERATION | 3 | 69 | 0.0005716 | 0.007732 |
344 | MITOTIC SPINDLE ORGANIZATION | 3 | 69 | 0.0005716 | 0.007732 |
345 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 4 | 163 | 0.0005773 | 0.007786 |
346 | SPINDLE ASSEMBLY | 3 | 70 | 0.0005962 | 0.008018 |
347 | REGULATION OF CELL ADHESION | 7 | 629 | 0.0006201 | 0.008315 |
348 | INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 4 | 168 | 0.0006466 | 0.008645 |
349 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 3 | 74 | 0.0007014 | 0.009352 |
350 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 2 | 17 | 0.0007188 | 0.009528 |
351 | NEGATIVE REGULATION OF LIPID STORAGE | 2 | 17 | 0.0007188 | 0.009528 |
352 | GRANULOCYTE MIGRATION | 3 | 75 | 0.0007294 | 0.009642 |
353 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 6 | 465 | 0.0007323 | 0.009652 |
354 | REGULATION OF TRANSPORT | 12 | 1804 | 0.0007349 | 0.009659 |
355 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 12 | 1805 | 0.0007385 | 0.00968 |
356 | CELLULAR RESPONSE TO ACID CHEMICAL | 4 | 175 | 0.0007533 | 0.009818 |
357 | HOMEOSTASIS OF NUMBER OF CELLS | 4 | 175 | 0.0007533 | 0.009818 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 43 | 7.5e-12 | 3.484e-09 |
2 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 70 | 4.204e-12 | 3.484e-09 |
3 | KINASE REGULATOR ACTIVITY | 10 | 186 | 1.459e-11 | 4.517e-09 |
4 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 7 | 51 | 2.657e-11 | 6.171e-09 |
5 | KINASE ACTIVITY | 16 | 842 | 3.737e-11 | 6.943e-09 |
6 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 16 | 992 | 4.19e-10 | 6.488e-08 |
7 | MOLECULAR FUNCTION REGULATOR | 18 | 1353 | 5.456e-10 | 7.242e-08 |
8 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 6 | 47 | 1.208e-09 | 1.402e-07 |
9 | ENZYME REGULATOR ACTIVITY | 15 | 959 | 2.596e-09 | 2.68e-07 |
10 | ENZYME BINDING | 19 | 1737 | 4.05e-09 | 3.763e-07 |
11 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 5 | 30 | 7.85e-09 | 6.63e-07 |
12 | CYTOKINE RECEPTOR BINDING | 9 | 271 | 1.172e-08 | 9.07e-07 |
13 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 4 | 15 | 3.585e-08 | 2.379e-06 |
14 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 4 | 15 | 3.585e-08 | 2.379e-06 |
15 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 5 | 42 | 4.588e-08 | 2.842e-06 |
16 | DEATH RECEPTOR BINDING | 4 | 18 | 7.994e-08 | 4.642e-06 |
17 | PROTEASE BINDING | 6 | 104 | 1.544e-07 | 8.436e-06 |
18 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 8 | 264 | 1.67e-07 | 8.62e-06 |
19 | PROTEIN KINASE ACTIVITY | 11 | 640 | 2.019e-07 | 9.87e-06 |
20 | CAMP BINDING | 4 | 23 | 2.294e-07 | 1.065e-05 |
21 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 4 | 30 | 7.013e-07 | 3.103e-05 |
22 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 9 | 445 | 7.936e-07 | 3.351e-05 |
23 | ADENYL NUCLEOTIDE BINDING | 15 | 1514 | 1.061e-06 | 4.285e-05 |
24 | PROTEIN HETERODIMERIZATION ACTIVITY | 9 | 468 | 1.205e-06 | 4.665e-05 |
25 | CYCLIC NUCLEOTIDE BINDING | 4 | 36 | 1.492e-06 | 5.544e-05 |
26 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 5 | 86 | 1.739e-06 | 6.214e-05 |
27 | KINASE INHIBITOR ACTIVITY | 5 | 89 | 2.062e-06 | 7.095e-05 |
28 | ENZYME INHIBITOR ACTIVITY | 8 | 378 | 2.497e-06 | 8.285e-05 |
29 | PROTEIN KINASE A BINDING | 4 | 42 | 2.806e-06 | 8.989e-05 |
30 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 3 | 16 | 6.667e-06 | 0.0002064 |
31 | RIBONUCLEOTIDE BINDING | 15 | 1860 | 1.35e-05 | 0.0004046 |
32 | PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY | 4 | 64 | 1.534e-05 | 0.0004452 |
33 | CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 23 | 2.084e-05 | 0.0005867 |
34 | DEATH RECEPTOR ACTIVITY | 3 | 24 | 2.378e-05 | 0.0006497 |
35 | PROTEIN DIMERIZATION ACTIVITY | 11 | 1149 | 5.51e-05 | 0.001457 |
36 | CYTOKINE RECEPTOR ACTIVITY | 4 | 89 | 5.646e-05 | 0.001457 |
37 | PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 5 | 178 | 5.982e-05 | 0.001502 |
38 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 5 | 184 | 7e-05 | 0.001711 |
39 | KINASE BINDING | 8 | 606 | 7.515e-05 | 0.00179 |
40 | RECEPTOR BINDING | 12 | 1476 | 0.000115 | 0.002671 |
41 | PEPTIDASE REGULATOR ACTIVITY | 5 | 214 | 0.0001424 | 0.003227 |
42 | PROTEIN PHOSPHATASE BINDING | 4 | 120 | 0.0001801 | 0.003984 |
43 | INSULIN RECEPTOR SUBSTRATE BINDING | 2 | 11 | 0.0002933 | 0.006337 |
44 | CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY | 3 | 56 | 0.000309 | 0.006523 |
45 | PHOSPHATASE ACTIVITY | 5 | 275 | 0.0004534 | 0.00936 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 13 | 237 | 6.431e-15 | 3.756e-12 |
2 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 1.878e-14 | 5.485e-12 |
3 | CATALYTIC COMPLEX | 20 | 1038 | 4.309e-14 | 8.387e-12 |
4 | MEMBRANE MICRODOMAIN | 12 | 288 | 2.109e-12 | 3.079e-10 |
5 | MEMBRANE PROTEIN COMPLEX | 17 | 1020 | 6.021e-11 | 7.033e-09 |
6 | CILIARY BASE | 5 | 23 | 1.876e-09 | 1.826e-07 |
7 | TRANSFERASE COMPLEX | 13 | 703 | 5.229e-09 | 4.363e-07 |
8 | PROTEIN KINASE COMPLEX | 6 | 90 | 6.492e-08 | 4.739e-06 |
9 | EXTRINSIC COMPONENT OF MEMBRANE | 7 | 252 | 1.898e-06 | 0.0001232 |
10 | PLASMA MEMBRANE PROTEIN COMPLEX | 9 | 510 | 2.444e-06 | 0.0001427 |
11 | PHOSPHATASE COMPLEX | 4 | 48 | 4.828e-06 | 0.0002563 |
12 | MEMBRANE REGION | 12 | 1134 | 8.565e-06 | 0.0004168 |
13 | CYTOSOLIC PART | 5 | 223 | 0.0001726 | 0.007755 |
14 | SARCOLEMMA | 4 | 125 | 0.0002107 | 0.008788 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04210_Apoptosis | 47 | 89 | 8.812e-118 | 1.586e-115 | |
2 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 18 | 136 | 1.166e-27 | 1.049e-25 | |
3 | hsa04662_B_cell_receptor_signaling_pathway | 14 | 75 | 9.318e-24 | 5.591e-22 | |
4 | hsa04660_T_cell_receptor_signaling_pathway | 15 | 108 | 2.296e-23 | 1.033e-21 | |
5 | hsa04380_Osteoclast_differentiation | 15 | 128 | 3.362e-22 | 1.21e-20 | |
6 | hsa04620_Toll.like_receptor_signaling_pathway | 14 | 102 | 9.478e-22 | 2.843e-20 | |
7 | hsa04722_Neurotrophin_signaling_pathway | 14 | 127 | 2.375e-20 | 6.107e-19 | |
8 | hsa04370_VEGF_signaling_pathway | 12 | 76 | 1.715e-19 | 3.858e-18 | |
9 | hsa04910_Insulin_signaling_pathway | 13 | 138 | 5.196e-18 | 1.039e-16 | |
10 | hsa04510_Focal_adhesion | 13 | 200 | 7.048e-16 | 1.269e-14 | |
11 | hsa04630_Jak.STAT_signaling_pathway | 11 | 155 | 5.797e-14 | 9.486e-13 | |
12 | hsa04973_Carbohydrate_digestion_and_absorption | 8 | 44 | 8.258e-14 | 1.239e-12 | |
13 | hsa04664_Fc_epsilon_RI_signaling_pathway | 9 | 79 | 1.766e-13 | 2.445e-12 | |
14 | hsa04150_mTOR_signaling_pathway | 8 | 52 | 3.458e-13 | 4.446e-12 | |
15 | hsa04914_Progesterone.mediated_oocyte_maturation | 9 | 87 | 4.342e-13 | 5.21e-12 | |
16 | hsa04062_Chemokine_signaling_pathway | 11 | 189 | 5.188e-13 | 5.837e-12 | |
17 | hsa04010_MAPK_signaling_pathway | 12 | 268 | 9.028e-13 | 9.559e-12 | |
18 | hsa04151_PI3K_AKT_signaling_pathway | 13 | 351 | 9.869e-13 | 9.869e-12 | |
19 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 7 | 42 | 6.29e-12 | 5.959e-11 | |
20 | hsa04012_ErbB_signaling_pathway | 8 | 87 | 2.526e-11 | 2.274e-10 | |
21 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 8 | 95 | 5.183e-11 | 4.442e-10 | |
22 | hsa04621_NOD.like_receptor_signaling_pathway | 7 | 59 | 7.72e-11 | 6.317e-10 | |
23 | hsa04014_Ras_signaling_pathway | 10 | 236 | 1.528e-10 | 1.196e-09 | |
24 | hsa04115_p53_signaling_pathway | 7 | 69 | 2.399e-10 | 1.799e-09 | |
25 | hsa04070_Phosphatidylinositol_signaling_system | 7 | 78 | 5.783e-10 | 4.164e-09 | |
26 | hsa04670_Leukocyte_transendothelial_migration | 7 | 117 | 1.014e-08 | 7.018e-08 | |
27 | hsa04720_Long.term_potentiation | 5 | 70 | 6.216e-07 | 4.093e-06 | |
28 | hsa04810_Regulation_of_actin_cytoskeleton | 7 | 214 | 6.367e-07 | 4.093e-06 | |
29 | hsa04622_RIG.I.like_receptor_signaling_pathway | 5 | 71 | 6.675e-07 | 4.143e-06 | |
30 | hsa04114_Oocyte_meiosis | 5 | 114 | 6.981e-06 | 4.188e-05 | |
31 | hsa04920_Adipocytokine_signaling_pathway | 4 | 68 | 1.952e-05 | 0.0001134 | |
32 | hsa04310_Wnt_signaling_pathway | 5 | 151 | 2.727e-05 | 0.0001534 | |
33 | hsa04020_Calcium_signaling_pathway | 5 | 177 | 5.824e-05 | 0.0003177 | |
34 | hsa04360_Axon_guidance | 4 | 130 | 0.0002448 | 0.001296 | |
35 | hsa00562_Inositol_phosphate_metabolism | 3 | 57 | 0.0003256 | 0.001674 | |
36 | hsa04640_Hematopoietic_cell_lineage | 3 | 88 | 0.00116 | 0.005802 | |
37 | hsa04120_Ubiquitin_mediated_proteolysis | 3 | 139 | 0.00426 | 0.02073 | |
38 | hsa04623_Cytosolic_DNA.sensing_pathway | 2 | 56 | 0.007678 | 0.03637 | |
39 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 2 | 168 | 0.05929 | 0.2736 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | CECR7 |
hsa-miR-130b-5p;hsa-miR-17-3p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-197-3p;hsa-miR-215-5p;hsa-miR-24-3p;hsa-miR-26b-5p;hsa-miR-335-3p;hsa-miR-361-5p;hsa-miR-491-5p;hsa-miR-590-3p | 12 | IL1R1 | Sponge network | 0.551 | 0.56177 | 0.097 | 0.93138 | 0.556 |
2 | EMX2OS |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-374b-5p;hsa-miR-421;hsa-miR-424-5p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-502-5p;hsa-miR-505-3p;hsa-miR-577;hsa-miR-663b;hsa-miR-93-5p | 25 | AKT3 | Sponge network | 1.057 | 0.31716 | 0.457 | 0.53933 | 0.542 |
3 | EMX2OS |
hsa-miR-130b-5p;hsa-miR-17-3p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-197-3p;hsa-miR-215-5p;hsa-miR-26b-5p;hsa-miR-30d-3p;hsa-miR-335-3p;hsa-miR-590-3p | 10 | IL1R1 | Sponge network | 1.057 | 0.31716 | 0.097 | 0.93138 | 0.517 |
4 | CECR7 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-1275;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-362-5p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-502-5p;hsa-miR-93-5p | 20 | AKT3 | Sponge network | 0.551 | 0.56177 | 0.457 | 0.53933 | 0.508 |
5 | CECR7 |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200a-3p;hsa-miR-20a-3p;hsa-miR-25-3p;hsa-miR-335-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-7-1-3p | 18 | IRAK3 | Sponge network | 0.551 | 0.56177 | 0.129 | 0.83349 | 0.45 |
6 | EMX2OS |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-16-1-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-188-5p;hsa-miR-200a-3p;hsa-miR-20a-3p;hsa-miR-25-3p;hsa-miR-32-5p;hsa-miR-324-5p;hsa-miR-335-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-374b-5p;hsa-miR-421;hsa-miR-452-3p;hsa-miR-505-3p;hsa-miR-577;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-660-5p;hsa-miR-7-1-3p;hsa-miR-92a-3p | 25 | IRAK3 | Sponge network | 1.057 | 0.31716 | 0.129 | 0.83349 | 0.42 |
7 | MEG3 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-577;hsa-miR-93-5p | 12 | AKT3 | Sponge network | 0.433 | 0.33816 | 0.457 | 0.53933 | 0.405 |
8 | CECR7 |
hsa-let-7f-1-3p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-32-3p;hsa-miR-335-5p;hsa-miR-582-3p;hsa-miR-590-3p;hsa-miR-590-5p | 11 | PIK3CA | Sponge network | 0.551 | 0.56177 | 0.023 | 0.97942 | 0.368 |
9 | CECR7 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-335-3p;hsa-miR-361-5p;hsa-miR-362-3p;hsa-miR-429;hsa-miR-590-3p | 10 | PRKAR2B | Sponge network | 0.551 | 0.56177 | -0.108 | 0.86421 | 0.346 |
10 | ZNF883 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-33a-3p | 10 | AKT3 | Sponge network | 0.913 | 0.16772 | 0.457 | 0.53933 | 0.3 |
11 | MEG3 |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-200a-3p;hsa-miR-20a-3p;hsa-miR-335-3p;hsa-miR-429;hsa-miR-577;hsa-miR-590-5p;hsa-miR-7-1-3p | 12 | IRAK3 | Sponge network | 0.433 | 0.33816 | 0.129 | 0.83349 | 0.279 |
12 | EMX2OS |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-32-5p;hsa-miR-335-3p;hsa-miR-362-3p;hsa-miR-452-5p;hsa-miR-590-3p;hsa-miR-92a-3p | 11 | PRKAR2B | Sponge network | 1.057 | 0.31716 | -0.108 | 0.86421 | 0.278 |
13 | EMX2OS |
hsa-let-7f-1-3p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-32-3p;hsa-miR-335-5p;hsa-miR-339-5p;hsa-miR-374b-5p;hsa-miR-576-5p;hsa-miR-582-3p;hsa-miR-590-3p | 13 | PIK3CA | Sponge network | 1.057 | 0.31716 | 0.023 | 0.97942 | 0.254 |